The GW VRU Director, Dr. David Diemert, co-authored an article assessing the value of public health, economic, and societal value of developing a vaccine to prevent and reduce the transmission of Schistosomiasis. Endemic in 78 countries, it is estimated that approximately 236 million people were treated for Schistosomiasis in 2019. This article evaluates the global public health need for a vaccine.
Vaccine Value Profile for Schistosomiasis
Latest News
This was a phase 2, randomized, open-label, non-placebo controlled trial to evaluate two partial doses o the Modified Vaccinia Ankara-Bavarian Nordin (MVA-BN) vaccine for protection against mpox.
This was a phase 1, double-blind trial to examine the safety and immunogenicity of a replication-competent recombinant vesicular stomatitis virus-vectored vaccine to reduce the risk of infection and severe illness from Lassa Fever.
The GW VRU is pleased to share the findings from a Phase 2 clinical trial that evaluated the effects of omicron-based COVID-19 vaccines in providing an increased level of protection against COVID-19 infection. This study adds to the evidence that matching COVID-19 vaccines to the circulating…